| Literature DB >> 32781642 |
Yuri E Sabutski1, Ekaterina S Menchinskaya1, Ludmila S Shevchenko1, Ekaterina A Chingizova1, Artur R Chingizov1, Roman S Popov1, Vladimir A Denisenko1, Valery V Mikhailov1, Dmitry L Aminin1,2, Sergey G Polonik1.
Abstract
A series of new tetracyclic oxathiine-fused quinone-thioglycoside conjugates based on biologically active 1,4-naphthoquinones and 1-mercapto derivatives of per-O-acetyl d-glucose, d-galactose, d-xylose, and l-arabinose have been synthesized, characterized, and evaluated for their cytotoxic and antimicrobial activities. Six tetracyclic conjugates bearing a hydroxyl group in naphthoquinone core showed high cytotoxic activity with EC50 values in the range of 0.3 to 0.9 μM for various types of cancer and normal cells and no hemolytic activity up to 25 μM. The antimicrobial activity of conjugates was screened against Gram-positive bacteria (Staphylococcus aureus, Bacillus cereus), Gram-negative bacteria (Pseudomonas aeruginosa and Escherichia coli), and fungus Candida albicans by the agar diffusion method. The most effective juglone conjugates with d-xylose or l-arabinose moiety and hydroxyl group at C-7 position of naphthoquinone core at concentration 10 µg/well showed antimicrobial activity comparable with antibiotics vancomicin and gentamicin against Gram-positive bacteria strains. In liquid media, juglone-arabinosidic tetracycles showed highest activity with MIC 6.25 µM. Thus, a positive effect of heterocyclization with mercaptosugars on cytotoxic and antimicrobial activity for group of 1,4-naphthoquinones was shown.Entities:
Keywords: 1,4-naphthoquinones; antibiotic activity; cytotoxic activity; quinoid compounds; quinone-sugar conjugates; thioglycosides
Mesh:
Substances:
Year: 2020 PMID: 32781642 PMCID: PMC7463537 DOI: 10.3390/molecules25163577
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthetic route for the synthesis of fused tetracyclic conjugates 4a–d.
Figure 1Starting derivatives of 5,8-dimethoxy-1,4-naphthoquinone.
Scheme 2Reagents and conditions for synthesis juglone bromomethoxyderivatives 11 and 12: (i) Br2, H2O2, CHCl3, rt; (ii) CH2N2/1,4-dioxane.
Figure 2Acetylated thioglycosides of substituted methoxy-1,4-naphthoquinones.
Figure 3Synthesized 1,4-naphthoquinone-thioglycoside tetracyclic conjugates.
Cytotoxicity (EC50) of oxathiine fused 1,4-naphthoquinone tetracycles on cancer and non-cancer cell lines (μM).
| Compound | Tested Cell Lines | |||
|---|---|---|---|---|
| Neuro 2a * | HeLa * | Ascites Ehrlich Carcinoma ** | Jb6 Cl 41-5a * | |
|
| >25 | >25 | >25 | >25 |
|
| - *** | - | - | - |
|
| >25 | >25 | >25 | >25 |
|
| >25 | >25 | >25 | >25 |
|
| 2.4 | 10.9 | 8.8 | 1.5 |
|
| 2.9 | 8 | 1.1 | 2.9 |
|
| 4.1 | 10.1 | 4.5 | 3.8 |
|
| 2.8 | 8.7 | 4.1 | 4.3 |
|
| 4.1 | 3.7 | 0.6 | 5.6 |
|
| 2.3 | 2.7 | 0.7 | 0.9 |
|
| 13.3 | 4.9 | 7.4 | 5.9 |
|
| 2.2 | 1.3 | 1.1 | 2.3 |
|
| 0.7 | 6.3 | 2.7 | 0.7 |
|
| 1.2 | 4.7 | 1.1 | 0.5 |
|
| 2.2 | 2.3 | 0.7 | 0.3 |
|
| 1.4 | 0.4 | 1.2 | 0.7 |
|
| >100 | >100 | >100 | >100 |
|
| 37.5 | 42.4 | 18.5 | 15.1 |
* Cytotoxicity evaluation with MTT reagent; ** cytotoxicity evaluation with with FDA; *** non-tested due to poor solubility.
Tumor cell selectivity (Selectivity Index (SI)) of tested tetracycles 18a–d–20a–d.
| Compound | Neuro-2a | HeLa | Ascitic Erclich Carcinoma |
|---|---|---|---|
|
| 0.6 | 0.1 | 0.2 |
|
| 1 | 0.4 | 2.6 |
|
| 0.9 | 0.4 | 0.8 |
|
| 1.5 | 0.5 | 1 |
|
| 1.4 | 1.5 | 9.3 |
|
| 0.4 | 0.3 | 1.3 |
|
| 0.4 | 1.2 | 0.8 |
|
| 1 | 1.8 | 2.1 |
|
| 1 | 0.1 | 0.3 |
|
| 0.4 | 0.1 | 0.5 |
|
| 0.1 | 0.1 | 0.4 |
|
| 0.5 | 1.75 | 0.6 |
|
| 0.4 | 0.4 | 0.8 |
Antimicrobial activity (zone inhibition) of oxathiine fused 1,4-naphthoquinone-thioglucoside tetracycles.
| Compound | Compound Concentration (µg/well) | Diameter of Zone Inhibition (mm) | ||||
|---|---|---|---|---|---|---|
| Gram-Positive Strains | Gram-Negative Strains | Fungus | ||||
|
|
|
|
|
| ||
|
| 100 | 0 | 0 | 0 | 0 | 0 |
|
| 100 | 0 | + | 0 | 0 | 0 |
|
| 100 | 0 | 0 | 0 | 0 | 0 |
|
| 100 | 0 | 0 | 0 | 0 | 8 ± 2 |
|
| 100 | + | 0 | 0 | 0 | 0 |
|
| 100 | 0 | 0 | 0 | 0 | 0 |
|
| 100 | 10 ± 2 | 16 ± 3 | 0 | 0 | 0 |
|
| 100 | 10 ± 2 | 16 ± 2 | 0 | 0 | 0 |
|
| 100 | 0 | 0 | 0 | 0 | 0 |
|
| 100 | 0 | 8 ± 2 | 0 | 0 | 0 |
|
| 100 | 8 ± 1 | 10 ± 2 | 0 | 0 | 0 |
|
| 100 | 20 ± 3 | 25 ± 2 | 0 | 0 | 0 |
|
| 100 | 30 ± 2 | 22 ± 1 | 0 | 0 | 0 |
| 10 | 10 ± 2 | 10 ± 2 | − | − | − | |
| 1 | 0 | 0 | − | − | − | |
|
| 100 | 30 ± 2 | 20 ± 1 | 0 | 0 | 0 |
| 10 | 0 | 10 ± 2 | − | − | − | |
| 1 | 0 | 0 | − | − | − | |
|
| 100 | 30 ± 2 | 25 ± 1 | 0 | 0 | 8 ± 1 |
| 10 | 25 ± 3 | 22 ± 2 | − | − | − | |
| 1 | + | + | − | − | − | |
|
| 100 | 40 ± 2 | 30 ± 3 | 0 | 0 | 0 |
| 10 | 25 ± 3 | 23 ± 2 | − | − | − | |
| 1 | 0 | + | − | − | − | |
|
| 100 | 0 | 0 | 12 ± 2 | 0 | − |
| 10 | 25 ± 2 | 25 ± 1 | 18 ± 2 | 22 ± 3 | − | |
| 30 | 20 ± 2 | 20 ± 3 | 0 | 0 | − | |
| 10 | − | − | − | − | 15 ± 2 | |
Zones within 20–40 mm mean strong antibiotic activity, zones up to 20 mm—moderate, ≤10 mm—weak, +—insignificant (− means that the study was not conducted).
Minimum inhibitory concentration (MIC, μM) and selectivity index (SI) of testing compounds against S. aureus.
| Compound | MIC | SI |
|---|---|---|
|
| 6.25 | 0.4 |
|
| 25.0 | - |
|
| 25.0 | - |
|
| 12.5 | 0.02 |
|
| 6.25 | 0.1 |
|
| >100.0 | - |